TY - JOUR AU - Linehan, W. M. AU - Srinivasan, R. AU - Schmidt, L. S. PY - 2010 DA - 2010// TI - The genetic basis of kidney cancer: a metabolic disease JO - Nat Rev Urol VL - 7 UR - https://doi.org/10.1038/nrurol.2010.47 DO - 10.1038/nrurol.2010.47 ID - Linehan2010 ER - TY - STD TI - Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau, M. Filipek, B. Melichar, E. Bajetta, V. Gorbunova, J.O. Bay, I. Bodrogi, A. Jagiello-Gruszfeld, and N. Moore. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370(9605):2103–11. ID - ref2 ER - TY - STD TI - Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier, C. Chevreau, E. Solska, A.A. Desai, F. Rolland, T. Demkow, T.E. Hutson, M. Gore, S. Freeman, B. Schwartz, M. Shan, R. Simantov, and R.M. Bukowski. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125–34. ID - ref3 ER - TY - STD TI - Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, S. Oudard, S. Negrier, C. Szczylik, S.T. Kim, I. Chen, P.W. Bycott, C.M. Baum, and R.A. Figlin. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115–24. ID - ref4 ER - TY - STD TI - Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, J.N. Atkins, J. Picus, P. Czaykowski, J. Dutcher, and E.J. Small. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010;28(13):2137–43. ID - ref5 ER - TY - STD TI - Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, C.H. Barrios, P. Salman, O.A. Gladkov, A. Kavina, J.J. Zarba, M. Chen, L. McCann, L. Pandite, D.F. Roychowdhury, and R.E. Hawkins. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061–8. ID - ref6 ER - TY - STD TI - Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, M.D. Michaelson, V.A. Gorbunova, M.E. Gore, I.G. Rusakov, S. Negrier, Y.C. Ou, D. Castellano, H.Y. Lim, H. Uemura, J. Tarazi, D. Cella, C. Chen, B. Rosbrook, S. Kim, and R.J. Motzer. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378(9807):1931–9. ID - ref7 ER - TY - JOUR AU - Hanahan, D. AU - Weinberg, R. A. PY - 2011 DA - 2011// TI - Hallmarks of cancer: the next generation JO - Cell VL - 144 UR - https://doi.org/10.1016/j.cell.2011.02.013 DO - 10.1016/j.cell.2011.02.013 ID - Hanahan2011 ER - TY - STD TI - Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, E. Staroslawska, J. Sosman, D. McDermott, I. Bodrogi, Z. Kovacevic, V. Lesovoy, I.G. Schmidt-Wolf, O. Barbarash, E. Gokmen, T. O'Toole, S. Lustgarten, L. Moore, and R.J. Motzer. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271–81. ID - ref9 ER - TY - STD TI - Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, V. Grunwald, J.A. Thompson, R.A. Figlin, N. Hollaender, A. Kay, and A. Ravaud. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. 2010;116(18):4256–65. ID - ref10 ER - TY - STD TI - Calvo E, Ravaud A, Bellmunt J. What is the optimal therapy for patients with metastatic renal cell carcinoma who progress on an initial VEGFr-TKI? Cancer Treat Rev. 2013;39(4):366–74. ID - ref11 ER - TY - JOUR AU - Bex, A. AU - Haanen, J. PY - 2011 DA - 2011// TI - Tilting the AXIS towards therapeutic limits in renal cancer JO - Lancet VL - 378 UR - https://doi.org/10.1016/S0140-6736(11)61655-3 DO - 10.1016/S0140-6736(11)61655-3 ID - Bex2011 ER - TY - STD TI - Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, B.J. Eigl, J.D. Ruether, T. Cheng, S. North, P. Venner, J.J. Knox, K.N. Chi, C. Kollmannsberger, D.F. McDermott, W.K. Oh, M.B. Atkins, R.M. Bukowski, B.I. Rini, and T.K. Choueiri. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27(34):5794–9. ID - ref13 ER - TY - JOUR AU - Dudek, A. Z. AU - Zolnierek, J. AU - Dham, A. AU - Lindgren, B. R. AU - Szczylik, C. PY - 2009 DA - 2009// TI - Sequential therapy with sorafenib and sunitinib in renal cell carcinoma JO - Cancer VL - 115 UR - https://doi.org/10.1002/cncr.24009 DO - 10.1002/cncr.24009 ID - Dudek2009 ER - TY - STD TI - Sablin MP, Negrier S, Ravaud A, Oudard S, Balleyguier C, Gautier J, Celier J. Medioni and B. Escudier. Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol. 2009;182(1):29–34. discussion 34. ID - ref15 ER - TY - JOUR AU - Escudier, B. PY - 2008 DA - 2008// TI - Signaling inhibitors in metastatic renal cell carcinoma JO - Cancer J VL - 14 UR - https://doi.org/10.1097/PPO.0b013e3181867605 DO - 10.1097/PPO.0b013e3181867605 ID - Escudier2008 ER - TY - STD TI - Tamaskar I, Garcia JA, Elson P, Wood L, Mekhail T, Dreicer R, B.I. Rini, and R.M. Bukowski. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol. 2008;179(1):81–6. discussion 86. ID - ref17 ER -